Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 209.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 168,194 shares of the company's stock after purchasing an additional 113,796 shares during the quarter. BNP Paribas Financial Markets owned 0.05% of Amneal Pharmaceuticals worth $1,332,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of AMRX. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth $81,000. Straightline Group LLC acquired a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth $92,000. Cibc World Markets Corp acquired a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth $118,000. Janney Montgomery Scott LLC acquired a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth $121,000. Finally, Fox Run Management L.L.C. lifted its holdings in shares of Amneal Pharmaceuticals by 69.0% during the fourth quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock worth $162,000 after purchasing an additional 8,342 shares during the period. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMRX has been the subject of several research analyst reports. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. StockNews.com cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Finally, Barclays increased their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $11.50.

Insider Buying and Selling

In related news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the sale, the director now owns 1,808,886 shares in the company, valued at approximately $16,099,085.40. This trade represents a 4.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. The trade was a 9.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.56% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Stock Down 1.3%

NASDAQ:AMRX opened at $7.50 on Tuesday. The company has a market capitalization of $2.35 billion, a PE ratio of -11.03 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.29 and a 52-week high of $9.48. The stock has a fifty day simple moving average of $7.74 and a 200-day simple moving average of $8.08.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.05. The business had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. As a group, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.